ravulizumab-cwvz (ultomiris) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It is designed to bind to and prevent the activation of Complement component 5 (C5).   Wikipedia

More Chemistry
  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Drug Pricing (per unit)

United States

$4890.9600 - $6307.4600
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

alxn1210 | ravulizumab-cwvz

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue